Drug Profile
Research programme: antiviral therapeutics - Bristol-Myers Squibb/Prosetta Biosciences
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Prosetta Corporation
- Developer Prosetta Biosciences
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors; Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Viral-infections in USA
- 31 Jul 2012 Early research in Viral infections in USA (unspecified route)